CHICAGO, Sept. 5 /PRNewswire-FirstCall/ -- Advanced Life Sciences Holdings, Inc. , will present seven posters on selected cethromycin therapeutic studies at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) at McCormick Place in Chicago, September 17 - 20. ICAAC, a key scientific event expected to attract more than 12,000 scientists from around the world, is a gathering of leading researchers and clinicians to discuss important themes and present the newest treatment advances in infectious disease. The Advanced Life Sciences booth, #643, will be located in Hall D in the Lakeside Center at McCormick Place.
(Logo: http://www.newscom.com/cgi-bin/prnh/20050428/CGTH039LOGO)
The Advanced Life Sciences poster presentations will discuss in vitro activity of cethromycin against key susceptible and resistant pathogens involved in community acquired pneumonia (CAP) as well as safety data in certain special clinical populations. Along with collaborators such as the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID), Eurofins Medinet, Micromyx and Battelle, the Company will present data demonstrating the potency of cethromycin against pathogens involved in bioterrorism.
In addition, Advanced Life Sciences is sponsoring a satellite symposium entitled “Drug Resistant CAP, Current and Future Treatments: Best Practices for Prevention and Management”. The panel, moderated by Gerald Donowitz, M.D., will feature presentations by Richard Wunderink, M.D., Joseph Blondeau, Ph.D. and B. Joseph Guglielmo, Jr., Pharm.D., all thought leaders in the field of infectious disease and microbiology. The satellite symposium is supported by Advanced Life Sciences through an unrestricted educational grant to the American Society for Microbiology and Conexus Health.
Symposium and Presentation Schedule Monday, September 17, 7:00 p.m. Central Daylight Time, Room E354A -- Satellite Symposium: Drug Resistant CAP, Current and Future Treatments: Best Practices for Prevention and Management Tuesday, September 18, 11:15 a.m. Central Daylight Time, Room E253D Poster Session 222: Pathogenesis and Therapeutics in Agents of Bioterrorism -- Poster: Poster B-2031: Efficacy of Cethromycin Against a Lethal Inhalation Anthrax Challenge in Rhesus Macaques Wednesday, September 19, 12:15 p.m. Central Daylight Time, Hall D Poster Session 176: Macrolides, Ketolides, Bicyclolides and Quinolones -- Poster E-1633: Assessment of In Vitro Activity of Cethromycin Against Telithromycin-resistant Strains of Streptococcus pneumoniae -- Poster E-1632: Assessment of In Vitro Activity of Cethromycin Against Strains of Streptococcus pneumoniae -- Poster E-1631: Assessment of In Vitro Activity of Cethromycin Against Strains of Haemophilus influenzae -- Poster E1634: Antimicrobial Activity of Cethromycin, a Novel Ketolide, Tested against a Diverse Collection of Francisella tularensis Strains Thursday, September 20, 9:00 a.m. Central Daylight Time, Hall D Poster Session 82: New Drug Pharmacokinetics -- Poster A-797: Evaluation of the Safety and Pharmacokinetics of Cethromycin Following Administration of Multiple Doses to Subjects with Severe Renal Impairment -- Poster A-796: Evaluation of the Safety and Pharmacokinetics of Cethromycin Following Administration of Single and Multiple Doses to Subjects with Mild or Moderate Chronic Hepatic Insufficiency
About ICAAC
The American Society for Microbiology (ASM) is hosting the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), which will be held in Chicago, Illinois, September 17 - 20, 2007. More than 12,000 physicians, researchers and other healthcare professionals from around the globe gather each year at ICAAC to foster worldwide solutions to the challenges of infectious diseases.
About Advanced Life Sciences
Advanced Life Sciences is a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, cancer and inflammation. The Company’s lead candidate, cethromycin, is a novel once-a-day antibiotic in late-stage clinical development for the treatment of respiratory tract infections.
Forward-Looking Statements
Any statements contained in this presentation that relate to future plans, events or performance are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, among others, those relating to technology and product development, market acceptance, government regulation and regulatory approval processes, intellectual property rights and litigation, dependence on collaborative relationships, ability to obtain financing, competitive products, industry trends and other risks identified in Advanced Life Sciences’ filings with the Securities and Exchange Commission. Advanced Life Sciences undertakes no obligation to update or alter these forward-looking statements as a result of new information, future events or otherwise.
Photo: http://www.newscom.com/cgi-bin/prnh/20050428/CGTH039LOGOPRN Photo Desk, photodesk@prnewswire.comAdvanced Life Sciences Holdings, Inc.
CONTACT: Joe Camp of Advanced Life Sciences Holdings, Inc.,+1-630-754-4352; or Media, Melanie Nimrodi, +1-312-546-3508, or Investors,Kathy Price, +1-213-486-6547, both of Financial Relations Board, forAdvanced Life Sciences Holdings, Inc.
Web site: http://www.advancedlifesciences.com//
